153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1899-1905

  Berger, M ^a   Grignani, G ^b   Giostra, A ^c   Ferrari, S ^d   Ferraresi, V ^e   Tamburini, A ^f   Cefalo, G ^g   Carnevale schianca, F ^b   Vassallo, E ^a   Picci, P ^d   Pagano, M ^a   Aglietta, M ^b   Pellerito, R E ^c   Fagioli, F ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

153samarium EDTMP administration; Hematopoietic stem cell rescue; Metastatic osteosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; LEXIDRONAM SAMARIUM SM 153; MORPHINE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FATALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INFECTION COMPLICATION; LOW DRUG DOSE; MALE; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; BONE TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; OSTEOSARCOMA; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864292921     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr542     Document Type: Article

References (33)

1. Link MP, Miser AW, Green AA et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 31425: 1600-1606.
2. Ward WG, Mikaelian K, Dorey F et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994; 12: 1849-1858.
3. Fagioli F, Aglietta M, Tienghi A et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002; 20: 2150-2156.
4. Kasper B, Lehnert T, Bernd L et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004; 34: 37-41.
5. Bielack SS, Kempf-Bielack B, Branscheid D et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009; 27: 557-565.
6. Schwarz R, Bruland O, Cassoni A et al. The role of radiotherapy in osteosarcoma. Cancer Treat Res 2009; 152: 147-164.
7. Resche I, Chatal JF, Pecking A et al. A dose-controlled study of 153Smethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583-1591.
8. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45: 91-99.
9. Anderson PM, Wiseman GA, Dispenzieri A et al. High-dose samarium-153 ethylenediamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 189-196.
10. Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005; 11: 6895-6900.
11. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with highdose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
12. Van Glabbeke M, Verweeij J, Judson I, Nielsen OS. EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
13. Dileo P, Morgan JA, Zahrieh D et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007; 109: 1863-1869.
14. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-1039.
15. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
16. Farhanghi M, Holmes RA, Volkert WA et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33: 1451-1458.
17. Bayouth JE, Macey DJ, Kasi LP, Fossella VF. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35: 63-69.
18. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005; 46: 18S-27S.
19. Eary JF, Collins C, Stabin M et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34: 1031-1036.
20. Weber DA, Eckerman KF, Dillman LT et al. MIRD: Radionuclide Data and Decay Schemes 1989; New YorkSociety of Nuclear Medicine.
21. Snyder WS, Fisher HL, Jr, Ford MR, Warner GG. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med 1969; 10: 5-52. MIRD Pamphlet No. 5.
22. Logan K, Volkert W, Holmes R. Radiation dose calculations in persons receiving injection of Sm-153-EDTMP. J Nucl Med 1987; 28: 505-509.
23. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
24. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
25. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992; 7: 131-177.
26. Bacci G, Longhi A, Bertoni F et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. Acta Orthop 2006; 77: 938-943.
27. Aung L, Gorlick R, Healey JH et al. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol 2003; 21: 342-348.
28. Jaffe N, Pearson P, Yasko AW et al. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer 2003; 98: 2457-2466.
29. Loeb DM, Garrett-Mayer E, Hobbs RF et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 2009; 115: 2514-2522.
30. Loeb DM, Hobbs RF, Okoli A et al. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 2010; 116: 5470-5478.
31. Essman SC, Lewis MR, Miller WH. Intraorgan biodistribution and dosimetry of 153Sm-ethylene-diaminetetramethylene phosphonate in juvenile rabbit tibia: implication for targeted radiotherapy of osteosarcoma. J Nucl Med 2005; 46: 2076-2082.
32. Kramer M, Weyrather WK, Scholz M. The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat 2003; 2: 427-436.
33. Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 2006; 12(20 Pt 2): 6250s-6257s.